In a single-center retrospective study, 4 RET fusion NSCLC patients and 1 RET-mutant NSCLC patient received ICIs treatment, and the mPFS and mOS were 3.0 months and 14.9 months, respectively (40). Here, RET is linked to non-small cell lung carcinoma.